SLC6A3 and Parkinson disease: Neuroimaging modalities such as DAT-SPECT and MRI are used to detection of early changes in brain structures and function [17], some studies investigate the use of biomarkers in blood and cerebrospinal fluid to detect the pathology of prodromal PD [18, 19].